Essex Investment Management Co. LLC Sells 37,529 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Essex Investment Management Co. LLC decreased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 14.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 231,214 shares of the biopharmaceutical company’s stock after selling 37,529 shares during the period. Essex Investment Management Co. LLC’s holdings in Amicus Therapeutics were worth $2,178,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of FOLD. Wellington Management Group LLP boosted its stake in shares of Amicus Therapeutics by 13.5% during the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after purchasing an additional 2,856,101 shares in the last quarter. Geode Capital Management LLC boosted its position in Amicus Therapeutics by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock valued at $70,499,000 after acquiring an additional 80,926 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Amicus Therapeutics by 4.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,160,027 shares of the biopharmaceutical company’s stock valued at $33,749,000 after acquiring an additional 139,491 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Amicus Therapeutics by 10.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after acquiring an additional 242,672 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its stake in shares of Amicus Therapeutics by 41.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company’s stock worth $12,916,000 after purchasing an additional 398,942 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have issued reports on FOLD. JPMorgan Chase & Co. lifted their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Wells Fargo & Company reduced their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Finally, StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Price Performance

NASDAQ FOLD opened at $8.86 on Monday. The stock’s fifty day moving average price is $9.43 and its 200 day moving average price is $10.24. Amicus Therapeutics, Inc. has a 1 year low of $8.78 and a 1 year high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The company has a market cap of $2.72 billion, a price-to-earnings ratio of -49.22, a PEG ratio of 1.51 and a beta of 0.69.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.